Xcovery nabs first FDA approval for lung cancer drug

The FDA has approved Xcovery Holdings' ALK inhibitor Ensacove for first-line treatment of adults with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer. The approval late Wednesday ...